New FDA Guidance Provides a Policy Designed to Expand the Availability of Respiratory Devices, Including Oxygen Concentrators, During the COVID-19 Pandemic

Today, the U.S. Food and Drug Administration (FDA) issued this immediately in effect guidance: Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease-2019 (COVID-19) Public Health Emergency.

WHITE OAK, MD  (Photo by Sarah Silbiger/Getty Images)

The FDA believes the policy set forth in this guidance may help address urgent public health concerns by helping to expand the availability of devices that facilitate respiration, including ventilators and accessories. Learn more.

Belluscura and its research partner, Separation Design Group, announce the filing of a patent application on a modular portable oxygen enrichment ventilation system

LONDON, UK, PLANO, TX AND WAYNESBURG, PA, March 13, 2020.  Belluscura PLC, in conjunction with its exclusive research partner Separation Design Group, announced today the filing of a patent application covering novel modular portable oxygen enrichment ventilation systems for treating patients suffering from chronic obstructive pulmonary diseases (COPD) and acute respiratory distress syndrome (ARDS) brought on by such diseases as COVID-19.

Read more

Belluscura announces filing of a patent application on an oxygen enrichment device and system for treating acute respiratory distress (ARDS), including ARDS caused by the recent Coronavirus

LONDON, UK AND PLANO, TX, February 6, 2020.  Belluscura PLC, in conjunction with its exclusive research partner Separation Design Group, announced today the filing of a patent application covering novel integrated portable extracorporeal oxygenation and carbon dioxide removal systems for treating patients suffering from acute respiratory distress syndrome (ARDS).

The latest patent application covers devices and systems for treating people suffering from ARDS including patients suffering from the recent coronavirus in Wuhan, China.  The primary cause of death from respiratory viruses like the coronavirus and influenza, are the result of the fluids accumulating inside the alveoli (the tiny air sacs of the lungs) which ultimately leads to the failure of the transfer of oxygen to and carbon dioxide out of the blood.  The current primary treatment for ARDS is oxygen therapy along with ventilator support.

Read more

Avoiding COPD Complications in the Summer

For people with COPD, summer heat and humidity can worsen their COPD symptoms, including shortness of breath and bronchospasms. However, while we cannot control the weather, we can control our environment and exposure to the summer heat – here are a few tips on preventing serious summertime complications:

Stay cool – if possible, stay indoors in air-conditioned areas. When driving, park in shady areas and use sun protectors in your car. Go outside for short periods of time, preferably in the early morning or later in the evening. Be sure to stay hydrated and avoid activities that involve utilizing extra energy.

Take your medications – remember to take your medications as directed by your doctor. If you use oxygen, talk to your doctor about your oxygen requirements during summer months.

Plan your activities – choose air-conditioned venues and indoor activities. Try to limit your outdoor activities to early morning or after the sun goes down. If you are going to be in a high-elevation area, talk to your doctor about your oxygen requirements.

Learn more about avoiding summertime COPD complications:

When to get a cough checked out

A cough is a common symptom of multiple conditions. Some conditions go away on their own, such as a common cold, while others, such as pneumonia, require medical attention and medication. How do you know when you should go see a doctor about your cough? That depends on multiple factors, including how long your cough has persisted and the symptoms that you have in addition to coughing – e.g. wheezing, shortness of breath, fever, coughing up blood.

Learn about the different conditions that can cause a cough, when you should see a doctor about your cough, the available treatments, and more:


LONDON, UK AND PLANO, TX  April 23, 2019.  Belluscura PLC is excited to announce that its crowdfunding campaign has exceeded the target raise of £500,000 ($647,000 USD). The campaign will remain open on Crowdcube ( until May 3 to allow additional people the opportunity to invest in the company.

This raise will enable Belluscura to continue moving forward with regulatory clearance of its novel X-PLO2R™ portable oxygen concentrator for use in treating patients suffering from COPD. Belluscura anticipates launching the X-PLO2R in the fourth quarter of 2019.

Read more

Belluscura reaches 91% of target on Crowdcube

A substantial new investment has brought our Crowdcube crowdfunding effort to 91% of our funding goal! We are thrilled and humbled to be supported by all the people who, like us, want to improve the lives of millions suffering from chronic lung diseases.

Belluscura well-received at the UK Investor Show

The Global Group UK Investor Show is UK’s number 1 investor event, owned by the Wray family. This year’s show took place March 30, featuring 125+ exhibitors and attracting 2,500 attendees.

Investors that visited the Belluscura booth had the opportunity to meet the company CEO Bob Rauker and CFO Tony Dyer and learn more about the X-PLO2R portable oxygen concentrator. The investors were impressed by how lightweight and small the X-PLO2R is, and by how quietly it operates. Multiple attendees also commented on how much the X-PLO2R would change the lives of people with chronic lung diseases:

Read more